Clinical utility of a blood-based BRAF V600E mutation assay in melanoma

BRAF inhibitors (BRAFi) have led to clinical benefit in patients with melanoma. The development of a blood-based assay to detect and quantify BRAF levels in these patients has diagnostic, prognostic, and predictive capabilities that could guide treatment decisions. Blood BRAF(V600E) detection and qu...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Mol Cancer Ther
मुख्य लेखकों: Panka, David J, Buchbinder, Elizabeth, Giobbie-Hurder, Anita, Schalck, Aislyn P, Montaser-Kouhsari, Laleh, Sepehr, Alireza, Lawrence, Donald P., McDermott, David F., Cohen, Rachel, Carlson, Alexander, Wargo, Jennifer A, Merritt, Ryan, Seery, Virginia J., Hodi, F. Stephen, Gunturi, Anasuya, Fredrick, Dennie, Atkins, Michael B., Iafrate, A. John, Flaherty, Keith T., Mier, James W, Sullivan, Ryan J
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2014
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4258469/
https://ncbi.nlm.nih.gov/pubmed/25319388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0349
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन